利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

10 条记录 (耗时 0.043 秒)

    IMAGE ANALYSIS FOR BREAST CANCER PROGNOSIS
    4.
    发明授权
    IMAGE ANALYSIS FOR BREAST CANCER PROGNOSIS 有权
    乳腺癌预后的图像分析

    公开(公告)号：EP2939026B1

    公开(公告)日：2017-07-05

    申请号：EP13815724.3

    申请日：2013-12-19

    申请人： Ventana Medical Systems, Inc. ,  Cleveland Clinic Foundation ,  The University of Melbourne

    发明人： CHUKKA, Srinivas ,  SARKAR, Anindya ,  SCHEMP, Crystal ,  SERTEL, Olcay ,  SINGH, Shalini ,  TUBBS, Raymond ,  WARING, Paul Michael ,  WICK, Nikolaus

    IPC分类号： G01N33/574 ,  G06F19/00

    CPC分类号： G06F19/3431 ,  G01N33/57415 ,  G01N2800/52 ,  G01N2800/54 ,  G06F19/00 ,  G06F19/22 ,  G06F19/321 ,  G16H50/30

    摘要： Heterogeneity for biomarkers in a tissue sample can be calculated. A heterogeneity score can be combined with an immunohistochemistry combination score to provide breast cancer recurrence prognosis. Heterogeneity can be based on percent positivity determinations for a plurality of biomarkers according to how many cells in the sample stain positive. An immunohistochemistry combination score can be calculated. An imaging tool can support a digital pathologist workflow that includes designating fields of view in an image of the tissue sample. Based on the fields of view, a heterogeneity metric can be calculated and combined with an immunohistochemistry combination score to generate a breast cancer recurrence prognosis score.

    摘要翻译： 可以计算组织样本中生物标志物的异质性。 异质性评分可以与免疫组织化学组合评分结合以提供乳腺癌复发预后。 根据样品中有多少细胞呈阳性染色，异质性可以基于多个生物标志物的百分比阳性确定。 可以计算免疫组化评分。 成像工具可以支持数字病理学家工作流程，其包括指定组织样本的图像中的视野。 基于视野，可以计算异质性度量并将其与免疫组织化学组合评分组合以产生乳腺癌复发预后评分。

    IMAGE ANALYSIS FOR BREAST CANCER PROGNOSIS
    5.
    发明公开
    IMAGE ANALYSIS FOR BREAST CANCER PROGNOSIS 有权
    BILDANALYSE ZUR BRUSTKREBSPROGNOSE

    公开(公告)号：EP2939026A1

    公开(公告)日：2015-11-04

    申请号：EP13815724.3

    申请日：2013-12-19

    申请人： Ventana Medical Systems, Inc. ,  Cleveland Clinic Foundation ,  The University of Melbourne

    发明人： CHUKKA, Srinivas ,  SARKAR, Anindya ,  SCHEMP, Crystal ,  SERTEL, Olcay ,  SINGH, Shalini ,  TUBBS, Raymond ,  WARING, Paul Michael ,  WICK, Nikolaus

    IPC分类号： G01N33/574 ,  G06F19/00

    CPC分类号： G06F19/3431 ,  G01N33/57415 ,  G01N2800/52 ,  G01N2800/54 ,  G06F19/00 ,  G06F19/22 ,  G06F19/321 ,  G16H50/30

    摘要： Heterogeneity for biomarkers in a tissue sample can be calculated. A heterogeneity score can be combined with an immunohistochemistry combination score to provide breast cancer recurrence prognosis. Heterogeneity can be based on percent positivity determinations for a plurality of biomarkers according to how many cells in the sample stain positive. An immunohistochemistry combination score can be calculated. An imaging tool can support a digital pathologist workflow that includes designating fields of view in an image of the tissue sample. Based on the fields of view, a heterogeneity metric can be calculated and combined with an immunohistochemistry combination score to generate a breast cancer recurrence prognosis score.

    摘要翻译： 可以计算组织样品中生物标志物的异质性。 异质性评分可与免疫组织化学组合评分相结合，以提供乳腺癌复发预后。 异质性可以基于多个生物标志物的百分比阳性测定，根据样品中多少个细胞染色阳性。 可以计算免疫组织化学组合评分。 成像工具可以支持包括在组织样本的图像中指定视野的数字病理学家工作流程。 基于视野，可以计算异质性度量，并与免疫组织化学组合评分相结合，产生乳腺癌复发预后评分。

    DETECTION OF IMMUNOGLOBULIN LIGHT CHAIN RESTRICATION BY RNA IN SITU HYBRIDIZATION
    7.
    发明公开
    DETECTION OF IMMUNOGLOBULIN LIGHT CHAIN RESTRICATION BY RNA IN SITU HYBRIDIZATION 有权
    RNA在原位杂交中检测免疫球蛋白轻链限制性

    公开(公告)号：EP3312296A1

    公开(公告)日：2018-04-25

    申请号：EP17202688.2

    申请日：2013-04-05

    申请人： Advanced Cell Diagnostics, Inc. ,  The Cleveland Clinic Foundation

    发明人： MA, Xiao-Jun ,  LUO, Yuling ,  TUBBS, Raymond

    IPC分类号： C12Q1/6886 ,  C07K16/00 ,  C12Q1/6881

    摘要： The invention provides a method for detecting immunoglobulin light chain restriction and clonality in B cells by RNA in situ hybridization assays on a sample of B cells from a subject. The detection is based on the pattern of signal associated with hybridized immunoglobulin kappa chain constant region (IGKCR) probe, immunoglobulin lambda chain constant region (IGLCR) probe, and immunoglobulin lambda-like polypeptide 5 (IGLL5) probe. The invention also provides a kit for conducting the RNA in situ hybridization assays.

    摘要翻译： 本发明提供了通过对来自受试者的B细胞样品进行RNA原位杂交测定来检测B细胞中的免疫球蛋白轻链限制性和克隆性的方法。 该检测基于与杂交的免疫球蛋白κ链恒定区（IGKCR）探针，免疫球蛋白λ链恒定区（IGLCR）探针和免疫球蛋白λ样多肽5（IGLL5）探针相关的信号模式。 本发明还提供了用于进行RNA原位杂交测定的试剂盒。

    DETECTION OF IMMUNOGLOBULIN LIGHT CHAIN RESTRICATION BY RNA IN SITU HYBRIDIZATION
    9.
    发明公开
    DETECTION OF IMMUNOGLOBULIN LIGHT CHAIN RESTRICATION BY RNA IN SITU HYBRIDIZATION 有权
    RESTRICTIONS EASIER免疫球蛋白检测中的RNA原位杂交

    公开(公告)号：EP2836607A1

    公开(公告)日：2015-02-18

    申请号：EP13772909.1

    申请日：2013-04-05

    申请人： Advanced Cell Diagnostics, Inc. ,  THE CLEVELAND CLINIC FOUNDATION

    发明人： MA, Xiao-Jun ,  LUO, Yuling ,  TUBBS, Raymond

    IPC分类号： C12Q1/68

    CPC分类号： C12Q1/6881 ,  C07K16/00 ,  C07K2317/515 ,  C12Q1/6886 ,  C12Q2600/158

    摘要： The invention provides a method for detecting immunoglobulin light chain restriction and clonality in B cells by obtaining a sample of B cells from a subject; conducting a duplex in situ hybridization assay on the sample using (i) at least one probe set which is designed to specifically hybridize to immunoglobulin kappa chain constant region (IGKCR) RNA; and (ii) at least one probe set which is designed to specifically hybridize to immunoglobulin lambda chain constant region (IGLCR) RNA; detecting signal associated with hybridized IGKCR probe and signal associated with hybridized IGLCR probe in a population of B cells in the sample; and determining a pattern of signal associated with hybridized IGKCR probe and hybridized IGLCR probe within individual cells in the B cell population, wherein the pattern of signal within individual cells indicates the presence or absence of light chain restriction and clonality of the B cells.